Table 3.

Overall estimate of incidence of anterior uveitis and CME based on prospective RCT data

Prostaglandin agent	Number at risk	Uveitis n (%)	CME n (%)	Surgical-related CME n (%)
Latanoprost	12 170	59 (0.48)	17 (0.14)	6 (0.05)
Bimatoprost	6746	1 (0.01)	0	0
Tafluprost	4605	0	0	0
Travoprost	2830	0	0	0
Latanoprostene Bunod	1391	0	0	0
Unoprostone	118	0	0	0
ONO 9054	93	2 (2.15)	0	0
Bimatoprost+travoprost	81	0	0	0
Latanoprost+travoprost	75	0	0	2 (2.67)
Latanoprost+tafluprost	67	0	0	0
Latanoprost+unoprostone	56	0	0	0

Using prospective data, the incidence of uveitis and CME among PGA users was 62/28 232 (0.22%) and 25/28 232 (0.09%), respectively.

Bimatoprost 0.3 mg/mL was used in the patient who developed uveitis.

CME, cystoid macular oedema; PGA, prostaglandin analogue; RCT, randomised controlled trial.